Xeltis’ Preclinical Aortic Valve Data at PCR London Valves
Positive preclinical data on Xeltis’ Aortic Valve (AV) have been shown at 2017 PCR London Valves meeting (24-26 September). The data set adds to the growing body of evidence indicating the potential of Xeltis’ restorative approach for a transcatheter aortic valve.
The data showed good hemodynamic performance for Xeltis’ AV at 3 and 6 months, with mean pressure gradients comparable to those of existing options and none to trace of regurgitation on average. Furthermore, the data showed a stable hemodynamic performance in the sub-cohort that completed 12-month follow-up.
“There is a real clinical need for alternative treatment options that overcome the durability issue of existing biological valves” – remarked Professor Spaulding, one of the authors of the poster – “considering the growing trend of TAVI procedures in younger and lower risk patients. A restorative approach could prove a highly beneficial treatment option,” he added.
PCR London Valves 2017 focuses on transcatheter therapies for valvular heart disease. It is considered the world’s largest educational meeting focused on the care of patients with valvular heart disease, specifically addressing percutaneous valve interventions.
Xeltis’ co-founder and CTO Martijn Cox also attended PCR London Valves as a panelist for the session: “Where will we be in 2025”; learn more about Xeltis’ CTO.